Computational biology

Iorio Group

Iorio group’s Apps, Tools and Computable Manuscripts

The Iorio Group works at the interface of biology, machine learning, statistics and information theory with the goal of understanding and predicting how genomic alterations and molecular traits from other omics contribute to pathological processes, biological circuits’ rewiring and have an impact on therapeutic response in human cancers and other diseases.

Our research aims at advancing human health by designing algorithms, computational tools and novel analytical methods for the integration and the analysis of pharmacogenomics and functional-genomics datasets, with the objective of identifying new therapeutic targets, biomarkers and drug repositioning opportunities.

With our experimental collaborators, we are contributing to the creation of a comprehensive map of all the genetic dependencies occurring in human cancers, and to the development of a computational infrastructure for translating this map into guidelines for early-stage drug development and precision medicine.

The Iorio Group designs, implements and maintains bioinformatics methods and original tools for the assessment of cancer pre-clinical models, the pre-processing, analysis and visualisation of genome-editing screening data, for the in-silico correction of new-technology-specific biases in such data, and for the optimization of single guide RNA libraries for pooled CRISPR-Cas9 screens and other experimental settings.

We are also interested in big-data analytics, the development of biomedical predictive models based on non-biomedical data, and computationally efficient constrained randomization strategies for testing combinatorial properties in large-scale genomic datasets and networks.

 

Group members

Publications

  • 05/2020 - Cell Systems

    CELLector: Genomics-Guided Selection of Cancer In Vitro Models

    Selecting appropriate cancer models is a key prerequisite for maximizing translational potential and clinical relevance of in vitro oncology studies. We developed CELLector: an R package and R Shiny application allowing researchers to select the most relevant cancer cell lines in a patient-genomic-guided fashion. CELLector leverages tumor genomics to identify recurrent subtypes with associated genomic signatures. It then evaluates […]

  • 12/2019 - Nature Communications

    Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets

    Genome-scale CRISPR-Cas9 viability screens performed in cancer cell lines provide a systematic approach to identify cancer dependencies and new therapeutic targets. As multiple large-scale screens become available, a formal assessment of the reproducibility of these experiments becomes necessary. We analyze data from recently published pan-cancer CRISPR-Cas9 screens performed at the Broad and Sanger Institutes. Despite […]